SCHEMBL9866485

SCHEMBL9866485

O=C(NC(=NCCCSc1ccccc1)NCCCc1c[nH]cn1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 4/20 0.42
HRH2 P25021 6/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RECQL P46063 1/20 0.41
HRH1 P35367 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HDAC1 Q13547 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10369046 1.00 HRH4 (0.42) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9867694 0.96 HRH2 (0.44) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9866763 0.95 NPC1 (0.42) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9867435 0.95 NPC1 (0.42) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9865867 0.94 HPGD (0.46) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9865876 0.94 HPGD (0.46) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL10369688 0.94 HRH4 (0.38) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL9866766 0.94 HRH2 (0.49) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL10369687 0.90 TDP1 (0.39) HRH4HRH2NPC1RAB9ASMN1; SMN2
SCHEMBL10369686 0.90 TDP1 (0.39) HRH4HRH2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed
EP-0199845-B1 IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HEUMANN PHARMA GMBH & CO (DE) 1990-08-01 EP disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed